Key facts
- Notable investors include Andreessen Horowitz, Bessemer Venture Partners, GV, BoxGroup, F-Prime Capital — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Curie.Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Curie.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curie.Bio
Operator of a biotech accelerator intended to improve the number of viable therapeutics companies created every year by helping them raise financing. The company offers to help biotech founders choose therapeutic targets, set milestones based on investor feedback, design experimental plans, interview and select drug discovery vendors, evaluate incremental data, and more, helping biotech companies to receive support and grow the company.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Employees
- 46
- Website
- curie.bio/
- Ownership
- Privately Held (backing)
Curie.Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curie.Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curie.Bio in its N-PORT filings yet. We sweep new filings monthly.